Clinical trial · no report yet · Phase 2
SOUNDTRACK-B
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- NCT06526793 ↗
- Recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- B-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL); Large B-Cell Lymphoma (LBCL)
- Interventions
- Surovatamig
- Arms
- Module 1: Surovatamig Monotherapy in Participants with Relapsed or Refractory Follicular Lymphoma · Experimental
- Module 2: Surovatamig Monotherapy in Participants with Relapsed or Refractory LBCL · Experimental
- Enrollment
- 270 (estimated)
- Primary outcomes
- Overall response rate (ORR) (central review)
- Sponsor
- AstraZeneca
- Start
- Nov 27, 2024
- Primary completion
- Apr 21, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06526793 · updated Oct 14, 2026